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ABSTRACT
We assessed the capacity of positively selected autologous CD133 hematopoietic stem cells (HSCs) to
reconstitute lymphomyelopoiesis in chronic lymphocytic leukemia (CLL) patients receiving myeloablative
chemotherapy. Ten resistant/relapsed CLL patients underwent HSC mobilization with chemotherapy and
granulocyte-colony stimulating factor (G-CSF). Positive selection of circulating CD133HSCs was performed
by immunomagnetic technique. Highly purified HSCs were reinfused after busulphan/melphalan myeloabla-
tive treatment. A median number of 4.2  106 CD34 cells/kg and of 3.14  106 CD133 cells/kg were
collected. Immunomagnetic selection resulted in the reinfusion of a median number of 2.45  106 CD133
cells/kg (median purity: 94.8%; median recovery: 84%) and 2.4  106 CD34 cells/kg (median purity: 93%;
median recovery: 71%). HSC selection resulted in a median T cell and CD19/CD5 cell depletion of 3.85 log
and 2.8 log, respectively. At the molecular level, however, 7 of 8 valuable purified HSC fractions were
contaminated by leukemic cells. All CLL patients showed rapid and sustained myeloid engraftment after
reinfusion of purified CD133 cells. Immunologic reconstitution was comparable to that routinely observed in
patients reinfused with unmanipulated leukapheresis products and no late infectious complications were
observed. With a median follow-up of 28 months for transplanted patients, 5 patients are in clinical complete
remission, 3 are in partial remission, and 1 is in progression. In conclusion, the reinfusion of highly purified
CD133 HSCs allowed the rapid and sustained recovery of hematopoiesis after myeloablative treatment in
resistant/relapsed CLL patients. However, the purging potential of positive selection of CD133 cells is not
adequate to achieve tumor-free autografts.
© 2007 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
CD133 is a novel antigen expressed on hematopoi-
tic stem cells (HSCs). CD 133 cells are present in the
eripheral blood (PB) of mobilized and nonmobilized
ndividuals, in the bone marrow (BM), in cord blood p
224CB), and are capable of long-term reconstitution of
uman hematopoiesis in immunodeﬁcient mice [1-3].
he expression of the CD133 antigen on HSCs is
argely superimposable to that of CD34. CD133 cells
an be cultured in vitro as well as CD34 or c-kitopulations [4,5], thereby suggesting that CD133 cells
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Transplantation of Highly Purified CD133 HSCs in CLL 1225hare similar growth factor requirements. However,
long with their hematopoietic potential, CD133
SCs give origin to the endothelial lineage and are
nown to contribute to neoangiogenesis after tissue isch-
mia and organ regeneration in animal models [6-8].
oreover, CD133 antigen is expressed on selected em-
ryonic stem cell lines [9], human fetal neural stem cells
ith the potential to repair damaged neural tissue [10],
onhematopoietic adherent cells [11], and multipotent
dult progenitor cells (MAPc), which can differentiate
n vitro and in vivo, at the single cell level, into
mbryonic stem cell-like cells with visceral mesoderm,
euroectoderm, and endoderm characteristics [12].
aken together, these studies clearly indicate that
D133 represents a cell surface marker for the iden-
iﬁcation of pluripotent human stem cells showing,
erhaps, a wider differentiation potential than CD34
ells.
The potential clinical beneﬁt of stem cell puriﬁ-
ation by positive selection of CD133 cells in com-
arison with CD34 cells is debatable [13-15]. Very
ew studies have recently evaluated the infusion of
llogeneic or autologous CD133 cells to support the
ecovery of BM function after myeloablative chemo-
herapy [13-15]. Although conclusive evidence is still
acking, stem cell puriﬁcation by CD133 expression
o reduce tumor cell contamination in autografts may
e considered for those disease(s) expressing CD34
ut not CD133 [15].
Chronic lymphocytic leukemia (CLL) is charac-
erized by the clonal proliferation and accumulation of
eoplastic B-lymphocytes (and much more rarely T
ells) in the blood, BM, lymph nodes, and spleen [16].
t present, there is no conventional curative treatment
or CLL. In addition, in the presence of poor risk
actors the median survival is short [17]. The use of
ew drugs, such as ﬂudarabine, produced a high num-
er of partial (PR) or complete (CR) clinical and
olecular remissions, especially in previously un-
reated patients, but only a marginal improvement of
verall survival (OS) [18]. Recently, there has been
onsiderable interest for antibody-based therapeutic
pproaches [19-21], and their use resulted in excellent
esponses in some patients, although the follow-up is
till short.
High-dose chemoradiotherapy followed by either
utologous or allogeneic stem cell transplantation
SCT) further improves the remission rate. Conven-
ional allogeneic SCT for CLL is associated with
igniﬁcant morbidity and mortality, both from regi-
en-related toxicity as well as from graft-versus-host
isease (GVHD) and infection. Retrospective data re-
orted from the European Bone Marrow Transplan-
ation Registry (EBMTR) showed a high number of
linical and molecular remissions with a 3-year dis-
ase-free survival (DFS) of 40% [22]. However, treat-
ent-related mortality (TRM) following allogeneic cCT in CLL patients was 46%, the mortality from
VHD being 20% [22]. A major advance in reducing
he short-term morbidity and mortality of SCT has
een the use of nonmyeloablative or reduced-intensity
onditioning regimens [23-25]. RIC regimens appear
o be associated with a decreased mortality after allo-
eneic transplantation, and allow transplantation in
lder patients, making this approach applicable to
ncreased numbers of CLL patients [23-25]. Patients
n these studies were often heavily pretreated and
efractory to therapy. Despite these poor prognostic
eatures, the majority of CLL patients demonstrated
onor engraftment and high CR rate [23,24], although
urvival was improved only in patients with chemosen-
itive disease. Taken together, these studies provided
erhaps the strongest direct evidence to date for a graft-
ersus-leukemia effect that can be exploited in the man-
gement of CLL.
A major drawback of allogeneic SCT is the limited
umber of CLL patients with an HLA-identical donor
26-28]. On the contrary, autologous stem cell trans-
lantation (ASCT) is applicable for almost every pa-
ient without important comorbidity under the age of
0 years, and induces complete responses in some
atients [26-31]. Although several studies have ad-
ressed the role of ASCT in the management of
ounger patients with CLL [29-31], its use remains
ontroversial, with the major problem being disease
elapse. In 1 study, on long-term follow-up of 137
atients who underwent autologous SCT with che-
osensitive disease, progression-free survival (PFS)
t 6 years was 30% (4%), with no evidence of a
lateau [26].
Multiparameter ﬂow cytometric and molecular
nalyses are used to investigate whether persistence of
inimal residual disease will predict clinical relapse
ollowing transplant in CLL. Moreover, there are
oncerns about the ability of CLL patients to mobilize
dequate numbers of progenitor cells, particularly af-
er ﬂudarabine therapy [26]. Furthermore, a major
rawback for the outcome of autologous transplan-
ation in CLL is the high frequency of malignant
ell contamination of BM and PB, which may con-
ribute to relapse after transplantation. This ﬁnding
as prompted investigations to develop effective
urging techniques, mainly based on positive
nd/or negative immunoselection [30,31]. How-
ver, the existence of CLL cells expressing the
D34 antigen cannot be excluded, and such “tumor
tem cells” might be enriched by puriﬁcation ac-
ording to CD34 expression [30].
On this rationale, we planned a pilot study for
esistant/relapsed CLL patients to assess the capacity
f positively selected autologous CD133 HSCs to
econstitute lymphomyelopoiesis after myeloablative
hemotherapy.
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A. Isidori et al.1226ATIENTS AND METHODS
atient Population
Twelve resistant/relapsed CLL patients were en-
olled between February 2003 and September 2005.
he characteristics of study patients are summarized
n Table 1. Patients with a histologic CLL diagnosis
ccording to the REAL/International Lymphoma
tudy Group Classiﬁcation [32] were eligible if they
ere between 18 and 65, relapsed or resistant after at
east 1 chemotherapy regimen, with adequate renal,
ardiac, and pulmonary function, a Karnofsky score
70%, or a WHO score 1. Exclusion criteria were
ge 18 or 65 years, major organ dysfunction, my-
losuppressive chemotherapy within the last 4 weeks,
D5 negativity, and uncontrolled organ infection. Pa-
ients with a positive test for human immunodeﬁ-
iency virus (HIV) or any form of active hepatitis were
lso excluded, as well as pregnant or nursing females.
ll patients were previously treated with ﬂudarabine-
ontaining regimens (Table 1). None of the patients
eceived Alemtuzumab before entering the study.
All subjects gave written informed consent before
ntering the study. The protocol was approved by the
nstitutional Ethics Committee and conformed to the
thical guidelines of the 1975 Declaration of Helsinki.
hemotherapy and Mobilizing Treatment
All patients received high-dose cyclophosphamide
7 g/m2) as mobilizing regimen. Granulocyte colony
able 1. Patient Characteristics
umber of patients 12
ex
Male 10
Female 2
edian age (range) 54 (46-62)
edian body weight (range) 73 (48-109)
ai Stage at diagnosis
0 —
I —
II 4
III 7
IV 1
edian diagnosis-ASCT interval in months
(range) 27 (10-138)
isease status
Partial response 10
Refractory 2
edian lines of prior chemotherapy (range) 2 (1-3)
atients receiving fludarabine before
entering the study (%) 100
edian number of prior cycles with
fludarabine (range) 4 (2-6)
edian time (months) from last cycle of
fludarabine and stem cell mobilization
(range) 5 (1-41)
edian extent of marrow infiltration at
time of study entry (range) 60 (10-90%)timulating-factor (G-CSF) (Filgrastim, Granulokine, dmgen Inc., Thousand Oaks, CA) at the dose of 5
g/kg/day was administered as a subcutaneous injec-
ion starting from day 6 after chemotherapy until
uccessful PBSC mobilization.
eukaphereses, PBSC Processing, and Positive
election of CD133 HSCs
Stem cell collection was started when the absolute
umber of circulating CD34 and CD133 cells was
20 cells/L [33-35] during the recovery phase from
igh-dose cyclophosphamide chemotherapy. PBSC
ere collected as already reported [33-35]. Standard
olume leukaphereses were performed daily until the
ollection of a minimum cell dose of 2 106 CD133
ells/kg was achieved; 1  106 CD133 cells/kg was
onsidered the minimum number of HSCs to proceed
o transplant. CD133 cells were selected with the
liniMACS® device and anti-CD133 monoclonal an-
ibody (MoAb) directly coupled to magnetic beads
CD133 Reagent, Miltenyi Biotec, Bergisch Glad-
ach, Germany) according to manufacturer’s instruc-
ions. Brieﬂy, CD133 cells were labeled with CD133
eagent, washed, and subsequently puriﬁed using
liniMACS® technology. After CD133 selection,
ells present in the positive and negative fractions
ere counted and submitted to ﬂow cytometry anal-
sis (see later). For exclusion of dead cells, 7-amino
ctinomycin D staining (PharMingen, San Diego, CA)
as included in all fractions. Cryopreservation and
torage in liquid nitrogen were performed by diluting
D133 cells in autologous plasma and 10% DMSO.
he cell suspension was cooled in a programmed
iologic freezing unit (CRYO 10-16, Planer, USA) at
°C/min to 40°C, then at 5°C/min to 100°C and
tored in the gas phase of a liquid nitrogen tank
ntil thawing [33]. At the time of reinfusion, HSCs
ere rapidly thawed at 37°C and reinfused via a cen-
ral line [33].
onditioning Regimen, Supportive Care, and
linical Monitoring
All patients were conditioned with oral busulphan
6 mg/kg/day over 4 days (days 6 to 2) and intra-
enous melphalan 140 mg/m2/day for 1 day (day 2)
efore reinfusion of CD133 autologous stem cells.
ll patients received 5 g/kg/day of ﬁlgrastim (Am-
en) starting on day 6 from autograft. Patients were
ursed in single or double rooms in reverse isolation
nd received antimicrobial prophylaxis that consisted
f oral nystatin and ciproﬂoxacin. Packed red blood
ells and platelet transfusions were administered to
aintain a hemoglobin level 8 g/dL and a platelet
ount10 109/L. Patients were treated with broad-
pectrum antibiotics when fever developed and the
NC was 0.5  109/L. Amphotericin B (1 mg/kg/
ay) was added if patients had persistent fever after 4-7
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Transplantation of Highly Purified CD133 HSCs in CLL 1227ays of intravenous antimicrobial therapy. Patients
nderwent daily assessment of symptoms and physical
xamination during hospitalization and weekly after
ischarge. As previously reported [34], laboratory
orkup was performed before transplant, daily during
he hospital stay, and weekly after discharge. Cotri-
oxazole and acyclovir were administered to CLL
atients for 3 months after ASCT to prevent Pneumo-
ystis carinii and viral infections, respectively.
mmunophenotypical Analysis
Flow cytometry analysis was performed by con-
entional dual color immunoﬂuorescence using a
anel of ﬂuorescein isothiocyanate (FITC)-conjugated
nd phycoerythrin (PE)-conjugated monoclonal anti-
odies (mAbs): 8G12-PE (HPCA2/CD34) anti-CD34,
LE-1-FITC (CD45), Leu-12-FITC (CD19), and
eu-1-PE (CD5) (Becton Dickinson, San Jose, CA).
E-conjugated anti-CD133 was purchased from Milte-
yi Biotec. Negative controls were isotype-matched ir-
elevant mAbs (Becton Dickinson). Brieﬂy, 100 L of
B in heparin-containing tubes (Becton Dickinson) were
ncubated for 15 minutes at room temperature with 10
L of mAbs. Red cell lysis (FACS™ Lysing Solution,
ecton Dickinson) was performed when appropriate.
he samples were then centrifuged, washed twice
ith phosphate buffer, and ﬁxed with 1% paraformal-
ehyde (Sigma, St. Louis, MO). Cells (1  105) were
cquired by ﬂow cytometer (FACSCalibur; Becton
ickinson) and analyzed by CellQuest software (Bec-
on Dickinson) [32-35]. The analysis was performed
xcluding cellular debris in a SSC/FSC dot plot. The
ercentage of positive cells was calculated subtracting
he value of the appropriate isotype controls. The
ensitivity for detection of CD19 CD5 CLL cells
y FACS was 1 tumor cell in 104 normal cells, as
hown in preliminary experiments with mixtures of
LL cells and leukapheresis products from normal
onors (data not shown).
olecular Analysis
Nucleic acid extraction, cDNA synthesis, iden-
iﬁcation of V-D-J gene rearrangement, and detec-
ion of contaminating CLL cells were performed as
reviously reported [36]. BM samples, samples of
nmanipulated leukapheresis, and highly puriﬁed
SC populations were analyzed at diagnosis, before
nd after positive selection of CD133 cells, and at
egular time points after transplant. No false-posi-
ive results were obtained when the RNA from
ther CLL patients was used for negative cross
ontrols. The sensitivity of the MRD detection
anged from 1 tumor cell in 104 to 107 cells (median
cell in 105). Clinical Endpoints
The primary endpoints of the study were: (1) to
ssess the capacity of positively selected CD133 cells
o reconstitute autologous hematopoiesis of CLL pa-
ients undergoing myeloablative chemotherapy, and
2) to assess the efﬁcacy of positive selection of
D133 cells to remove neoplastic CLL cells from
utologous grafts (indirect purging). Secondary end-
oints were: (1) to determine the immunologic recon-
titution of CLL patients receiving myeloablative che-
otherapy and reinfusion of CD133 cells; (2) to
ssess the molecular complete remission rate (MCR);
nd (3) to assess the safety of this procedure, consid-
red as the incidence of adverse event (grading accord-
ng to WHO) and clinically signiﬁcant abnormal lab-
ratory value following reinfusion of highly puriﬁed
D133 cells.
tatistical Analysis
The results are presented as median values and
anges. The correlation between the number of
D34 and CD133 cells infused and the time to
ematopoietic recovery were assessed by the Pearson’s
orrelation test.
ESULTS
Twelve CLL patients entered in the study. Two of
2 patients did not mobilize the minimum number of
BSC to proceed to transplantation procedures. Con-
ersely, 10 patients underwent leukaphereses followed
y positive selection of CD133 cells. Nine out of 10
atients were then transplanted, as 1 patient withdrew
he informed consent to ASCT while in CR. Finally,
nly 8 of 9 patients undergoing ASCT were valuable
or molecular analysis.
ell Processing and Purging Results
A median number of 4.2  106 CD34 cells/kg
range: 2.75-8.62) and of 3.14  106 CD133 cells/kg
2.25-7.18) were collected from the PB after mobili-
ation with high-dose cyclophosphamide and G-CSF.
mmunomagnetic selection with CD133 reagents al-
owed the reinfusion of a median number of 2.45 
06 CD133 cells/kg (1.51-6.41) with a median purity
f 94.8% (76.5-99.5) and a median recovery of 83.5%
66.5-100), and 2.4  106 CD34 cells/kg (1.15-6.5)
ith a median purity of 93% (73.8-99.5) and a median
ecovery of 71% (45-82) (Table 2). Positive selection
f CD133 cells resulted in a median T cell depletion
f 3.85 log (1.6-4.5) and in the median purging of 2.8
og (1-4.5) of CD19/CD5 cells (Table 3). Each
ositive selection required only 1 column and 1
D133 tubing set.
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A. Isidori et al.1228yeloid Engraftment
Nine of 10 CLL patients were reinfused with
ighly puriﬁed CD133 HSCs, and their rapid my-
loid engraftment is shown in Table 4. One patient in
linical CR before HSC collection refused ASCT.
onsistent with the fast hematopoietic reconstitution,
he percentage of documented infections was low and
he hospital stay after ASCT was short (Table 4). No
igniﬁcant correlation was found between the number
f CD133 cells reinfused and time to neutrophil and
latelet engraftment (data not shown). The extra-he-
atologic toxicity of ASCT supported with positively
elected CD133 HSCs was mild: 1 patient showed
HO grade III oral mucositis and 1 patient had grade
V nausea/vomiting. One additional patient was read-
itted into the hospital after developing a grade II-III
inusoidal obstructive syndrome (SOS) 30 days after
he busulphan-containing conditioning regimen. Af-
er appropriate medical therapy the patient fully re-
overed from the SOS and she is now alive and well at
1 months from ASCT.
mmunologic Reconstitution and Late
nfectious Complications
Figures 1 and 2 show the immunologic reconsti-
ution of CLL patients after transplantation of
D133 HSCs. The recovery of CD3, CD4,
D8 T lymphocytes and CD16/CD56 natural
iller cells is reported in Figure 2, whereas Figure 1
hows white blood cell and B cell reconstitution. The
otal lymphocyte count as well as the number of
D3, CD8, and natural killer cells returned to
aseline value by 1 month after transplantation. As
xpected, the median value of CD4 cells remained
elow 0.5  109/L up to 18 months after ASCT, and
able 2. Median Number of CD34 and CD133 Cells before and
fter the Selection Procedure (10 Patients)
Median
Values Collected Reinfused Recovery (%)
D34 cells
106/kg 4.2 (2.75-8.62) 2.4 (1.15-6.5) 71 (45-82.3)
% 0.85 (0.37-3.22) 93 (73.8-99.5)
D133cells
106/kg 3.14 (2.25-7.18) 2.45 (1.51-6.41) 83.5 (66.5-100)
% 0.66 (0.33-2.68) 94.8 (76.5-99.5)
able 3. Median Number of CD3 and CD5/19 Cells before and aft
Median Values Collected
D3cells
104/kg 1710 (957-5038)
% 4.18 (1.1-19.8)
D5/CD19cells
104/kg 813.5 (0-79,927)
% 1 (0-91.8)ecame higher than baseline levels at 2 years after
SCT (Fig. 2). Clinically, no infectious complications
ere observed and none of the patients were readmit-
ed in the Hospital for late infections.
linical and Molecular Follow-up
All mobilizing patients (10) are evaluable for
linical follow-up, and 8 of 10 for molecular follow-
p. With a median follow-up of 28 months for trans-
lanted patients, 5 patients are in CR, 3 are in PR, and
is in progression. Three patients improved the clin-
cal status after ASCT from PR to CR. At the molec-
lar level, 7 of 8 valuable patients were reinfused with
uriﬁed HSC populations still containing detectable
eukemic cells (Table 5). Evaluation of molecular min-
mal residual disease at 6 months after ASCT showed
he persistence of CLL cells in all evaluable patients.
ISCUSSION
CLL remains an incurable disease and, notwith-
tanding the excellent remission rates now achieved
ith purine analogs and mAbs, the vast majority of
atients with CLL relapse after primary treatment
26]. With many potential treatments available, the
equence of treatments and the timing of procedures
uch as SCT remain controversial. Myeloablative al-
ogeneic SCT is associated with increased morbidity
nd mortality. Although no direct comparisons of my-
loablative and nonmyeloablative transplants have
een performed for patients with CLL, given their
election Procedure (10 Patients)
Reinfused Purging (log)
0.56 (0.09-15.2) 3.85 (1.6-4.5)
0.29 (0.02-5.8)
1.7 (0-4.8) 2.8 (1-4.5)
able 4. Engraftment Data (9 Patients)
Median Range
ays to ANC >0.5  109/L 11 10-16
ays to PLT > 20  109/L 12 11-18
ays to PLT > 50  109/L 31 15-75
ocumented infections (% of patients) 33 —
arenteral antibiotics days 4 0-6
ays on G-CSF after ASCT* 8 6-13
ays to hospital discharge 14 12-19
NC indicates absolute neutrophil count; PLT, platelet count;
ASCT, autologous stem cell transplantation; G-CSF, granulo-
cyte-colony stimulating factor.
All patients received 5 g/kg/day of ﬁlgrastim starting on day 6
after autograft.er the S0.26 (0-1.54)
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Transplantation of Highly Purified CD133 HSCs in CLL 1229lder age, it seems most reasonable to consider non-
yeloablative conditioning regimen transplants as the
pproach of choice for CLL patients in whom alloge-
eic transplant is being considered. Several prospec-
igure 1. Immunologic reconstitution of normal and leukemic B
utologous CD133 HSCs.
igure 2. Immunologic reconstitution of T lymphocytes and NK
D133 HSCs.ive multicenter trials [27-30] have addressed the role
f ASCT in the management of patients with CLL. Its
se still remains controversial, with a signiﬁcant de-
rease in the number of these procedures after the
hocytes in CLL patients after transplantation of highly puriﬁed
CLL patients after transplantation of highly puriﬁed autologouslympcells in
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A. Isidori et al.1230ntroduction of RIC transplants and chemoimmuno-
herapy strategies.
Some studies demonstrated that high-dose ther-
py followed by autologous stem cell rescue can in-
uce or maintain long-term complete remission [27-
0]. However, disease relapse almost inevitably occurs
fter ASCT in CLL patients with the potential con-
ribution of reinfused tumor cells. Immunomagnetic
election of CD34 cells is widely considered one of
he most efﬁcient methods of depletion of unwanted
ells from PBSC grafts, resulting, for example, in B
ells reduction of about 3 logs [33-35,37-38]. How-
ver, probably because of the high contamination of
eukemic cells prior to purging procedures, most
BSC grafts from CLL patients contain residual tu-
or cells after conventional CD34 cell selection
30-31]. In addition, the existence of CLL cells ex-
ressing the CD34 antigen cannot be excluded; such
tumor stem cells” might be enriched by puriﬁcation
ccording to CD34 expression [30]. In fact, at least 2
tudies addressed the question of the involvement of
D34 cells as a part of the malignant cell clone of
atients with B-CLL [39-40]. In an elegant experi-
ental model, Gahn and collaborators [39] tested BM
nd PB samples from 75 patients with B-CLL for the
resence of trisomy 12 or the deletion of the retino-
lastoma (Rb) gene by ﬂuorescence in situ hybridiza-
ion. CD34 subpopulations were isolated by ﬂuores-
ence-activated cell sorting and analyzed for the
resence of the informative genetic marker. Trisomy
2, as well as Rb deletion, was detected in 20% of
atients. In 7 patients with trisomy 12, hematopoietic
rogenitor cells were sorted, and the genetic marker
as detected in the CD34/CD38 cells as well as in
he CD34/38 subsets in 3 patients. Progenitor cells
ere also sorted in 2 patients with Rb deletion. In 1
atient, Rb deletion was present in 10% of CD34/
able 5. Molecular Follow-up of CLL Patients Submitted to ASCT
ith Positively Selected CD133 HSCs
Patient
Status at
Study
Entry In
Vivo Leukapheresis
Positively
Selected
CD133
HSCs
Follow-up
(6 Months
after
ASCT)
1    
2    
3    
4   ND ND
5    
6 NE NE NE NE
7    
8    
9    
10    
indicates PCR positive; , PCR negative; NE, not evaluable;
ND, not done.8 cells of only 1 patient. The authors concluded mhat the malignant transformation in B-CLL may in-
olve early HSCs, and place a note of caution on
trategies using ASCT. Although the expression of the
D133 Ag on HSCs is largely superimposable to that
f CD34, there is no evidence, at present, of the
otential involvement of CD133 in the B-CLL neo-
lastic clone. In this view, preliminary experiments
rom our laboratory did not show the coexpression of
D133 on CD19/CD5 leukemic cells (data not
hown).
Based on these considerations, we designed a pilot
tudy: (1) to assess the capacity of positively selected
D133 cells to reconstitute autologous hematopoi-
sis of CLL patients undergoing myeloablative che-
otherapy, and (2) to assess the efﬁcacy of positive
election of CD133 cells to remove neoplastic CLL
ells from autologous grafts (indirect purging).
The main objective of our study was to demon-
trate the safety of autografting with highly puriﬁed
utologous CD133 HSCs. The most important de-
erminants of safety were considered: (1) engraftment,
2) incidence of unexpected severe adverse event, and
3) infectious complications.
All patients had a rapid and sustained engraftment,
ith a median time to achieve an ANC count of 0.5 
09/L and a platelet count of 20  109/L similar to
hose expected from infusion of the same number of
D34 cells in an unmanipulated autograft
33-35,37,38]. No signiﬁcant correlation was found
etween the number of CD133 cells reinfused and
ime to neutrophil and platelet engraftment.
Consistent with the fast hematopoietic reconstitu-
ion, the percentage of documented infections was low
nd the hospital stay after ASCT was short. After the
ransplant, all patients rapidly recovered a number of
D4 T lymphocytes200/L. None of the patients
xperienced a CMV reactivation nor other opportu-
istic infections after hospital discharge. The extra-
ematologic toxicity of ASCT supported with posi-
ively selected CD133HSCs was mild: only 1 patient
eveloped an unexpected severe adverse event (a grade
I-III sinusoidal obstructive syndrome).
The tumor burden of most of the patients enrolled
n this study was very high at the time of stem cell
ollection (median marrow inﬁltration, 60%; Table
), which resulted in a high tumor cell load in the
eukapheresis products prior to positive selection of
D133 cells. Thus, in our study, CD133 HSC
election resulted in a median CD19/CD5 deple-
ion of 2.8 log with detectable tumor cells in 7 of 8
valuable puriﬁed HSC fractions, whereas double
positive/negative) selection techniques described by
everal groups [30,31] were able to produce a purging
fﬁcacy of about 5 logs.
With a median follow-up of 28 months for trans-
lanted patients, 5 patients are in clinical, but not
olecular, CR, 3 are in PR, and 1 is in progression.
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Transplantation of Highly Purified CD133 HSCs in CLL 1231hree patients improved the clinical status after
SCT from PR to CR. The follow-up of our cohort
f patients is very short, and therefore, no speculation
an be made on the long-term impact of this strategy.
oreover, the study was neither designed nor pow-
red to assess the clinical efﬁcacy of this procedure to
nduce complete clinical and molecular remissions.
In conclusion, positive selection and transplanta-
ion of autologous highly puriﬁed CD133 stem cells
n resistant/relapsed CLL patients resulted in rapid
ematopoietic reconstitution without an adequate leu-
emic cell purging.
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